JP Morgan Upgrades Karyopharm Therapeutics to Neutral, Announces $8 Price Target
JP Morgan analyst Eric Joseph upgrades Karyopharm Therapeutics (NASDAQ:KPTI) from Underweight to Neutral and announces $8 price target.
Karyopharm Shares Fall After Selinexor Data In Endometrial Cancer Patients
Karyopharm Therapeutics Inc's (NASDAQ: KPTI) Phase 3 SIENDO selinexor study has
35 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday.
Recap: Karyopharm Therapeutics Q4 Earnings
Karyopharm Therapeutics (NASDAQ:KPTI) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar
Here's a roundup of top developments in the biotech space over the last 24 hours:
Karyopharm Therapeutics Q4 EPS $(0.51) Misses $(0.49) Estimate, Net Product Revenue $29.8M
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.49) by 4.08 percent. This is a 13.56 percent increase over losses of $(0.59) per
Earnings Scheduled For February 8, 2022
Companies Reporting Before The Bell
• Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion.
Karyopharm Receives Orphan Drug Designation From FDA For Eltanexor For The Treatment Of Myelodysplastic Syndromes
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug